Business Wire

Octapharma to Sponsor Two Symposia at the 2016 World Federation of Hemophilia (WFH) World Congress in Orlando, USA

22.7.2016 12:16 | Business Wire

Del

Octapharma will sponsor a range of activities at this year’s WFH World Congress in Orlando, USA, including two symposia and a number of posters and scientific presentations highlighting Octapharma’s recent developments in haemophilia A and von Willebrand disease (VWD).

The first symposium, “Simple solutions to complex issues: Addressing today’s challenges in VWD and haemophilia A” on Monday 25 July 2016, will be chaired by Professor Erik Berntorp (Lund University, Malmö, Sweden) and will explore current clinical issues in the management of patients with VWD and haemophilia A. New insights into prophylactic therapy for VWD patients will be discussed, including the management of bleeding in patients in the perioperative setting, and special issues related to VWD in women will be addressed. The latest clinical experiences with wilate®, a high purity, double virus-inactivated VWF/FVIII concentrate containing both factors in a physiological 1:1 ratio, will be presented including its use in immune tolerance induction in haemophilia A patients with FVIII inhibitors.

Major challenges in current haemophilia A treatment include the development of inhibitors and the need for frequent venous access for FVIII injection. Octapharma’s human cell line recombinant FVIII Nuwiq® (Human-cl rhFVIII)®, is a fourth generation rFVIII derived from a human cell line without chemical modification or fusion with any other protein and is devoid of antigenic non-human epitopes1,2. The development aim of Nuwiq® is to address the challenges of FVIII inhibitors and frequent infusions required during prophylaxis.

The second symposium, “A focus on human cell-line derived rFVIII in haemophilia A: Update on clinical experience with Nuwiq® in PUPs and PTPs” on Wednesday 27 July, will be chaired by Professor Craig Kessler (Georgetown University Medical Centre, Washington DC, USA) and will provide an opportunity to discuss the current complex issues in haemophilia A and the latest experience with Nuwiq®. The risk of inhibitor development throughout the life of haemophilia A patients, taking into account factors such as age and the need for intensive treatment during surgery will be reviewed. New interim data from a clinical study of Nuwiq® in previously untreated patients (PUPs) will be presented, as well as the importance of PK-guided personalised prophylaxis and its potential to reduce the number of infusions and bleeding rates.

In addition, the following scientific posters will be presented during the congress:

Nuwiq-Focused Posters:

  • Individualized prophylaxis with Nuwiq® (Human-cl rhFVIII) in previously treated adults with severe haemophilia A who had received regular routine prophylaxis in the past
  • PUPs with Severe Haemophilia A - A GCP Study Evaluating the Immunogenicity, Efficacy and Safety of Nuwiq® (NuProtect)
  • Individual baseline thrombin generation and bleeding rate during personalized prophylaxis with Nuwiq® in previously treated patients with severe haemophilia A
  • Long-term Immunogenicity, Safety and Efficacy of Human-cl rhFVIII in Previously Treated Children with Severe Haemophilia A
  • Experience with Nuwiq® in clinical trials with previously treated paediatric and adult patients

Wilate-Focused Posters:

  • Surveillance Study of Safety and Efficacy of a VWF/FVIII concentrate in patients with von Willebrand disease (VWD) – data report from an ongoing study (Wil-20)

Octanate-Focused Posters:

  • Immune tolerance induction in haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study (ObsITI)
  • Disease severity as a predictor of response to immune tolerance induction (ITI) in adult patients with haemophilia A and high titer inhibitors

Fibrinogen-Focused Posters:

  • Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: final analysis.

About von Willebrand Disease

VWD is the most common of the inherited bleeding disorders, with approximately 1% of the population having VWF levels below normal. VWD is classified as type 1 (generally mild), type 2 (variable) or type 3 (severe). The symptoms of VWD are usually those of platelet dysfunction and include nose bleeds, skin bruises and haematomas, prolonged bleeds from trivial wounds, oral cavity bleeding, and excessive menstrual bleeding. Gastrointestinal bleeds are relatively rare, but may be very serious when they occur. Severe deficiency of VWF, or a specific defect in the interaction of VWF with FVIII, causes a secondary moderate deficiency of FVIII. These patients may have symptoms that are more characteristic of haemophilia, such as bleeds into joints or soft tissues including muscle and brain.

About Haemophilia A

Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which if left untreated leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 38%.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.

Octapharma employs approximately 6,400 people worldwide to support the treatment of patients in 105 countries with products across three therapeutic areas:

• Critical Care

• Haematology (coagulation disorders)

• Immunotherapy (immune disorders)

Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.

For more information visit www.octapharma.com

References:

1. FDA Memorandum to Octapharma dated 09 October 2014, reference STN 125555\0

2. Kannicht et al. Thrombosis Research 2013; 131: 78–88

Contact information

Octapharma AG
Corporate Communications
Claudie Qumsieh
Tel.: +(41)-55-451-21-78
claudie.qumsieh@octapharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

Permasteelisa Group to Join Grandland21.8.2017 04:11Pressemelding

Worldwide leading contractor in engineering, project management, manufacturing and installation of architectural envelopes and interior systems, Permasteelisa Group, will join forces with Grandland Group – a fast growing, Shenzhen-based specialist in design and construction of architectural decoration. The strategic alliance will create the biggest, most comprehensive curtain wall player in the world, with exceptional potential for further growth for both companies. Permasteelisa will remain fully committed to build avant-garde architectures and top end, high-quality projects which have become its trademark. The news comes today after LIXIL Group Corporation (LIXIL Group) (TOKYO: 5938) – a global leader in the housing and building industry – announced that it has decided to sell 100% of shares of Permasteelisa S.p.A., held by its major subsidiary LIXIL Corporation, to Grandland Holding

LIXIL to Sell Permasteelisa to Grandland21.8.2017 03:42Pressemelding

LIXIL Group Corporation (LIXIL Group) (TOKYO:5938), a global leader in the housing and building industry, today announced that it has decided to sell 100% of the shares of Permasteelisa S.p.A (Permasteelisa) held by its major subsidiary LIXIL Corporation to Grandland Holdings Group Limited (Grandland), a leading Chinese architectural design and construction company. The transaction is subject to customary closing conditions and regulatory approvals, including in China, the United States and Russia. Under the terms of the agreement, the base sale price for Permasteelisa is EURO 467 million. As a result of this transaction and the deconsolidation of Permasteelisa from LIXIL Group, LIXIL Group’s revenue for the full fiscal year ending March 2018 is expected to decrease by approximately 170.0 billion yen from the amount announced on May 8, 2017 (by approximately 9.2% of the previously fore

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom